Lido Advisors’s AbbVie ABBV Stock Holding History

Lido Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$87K	Buy	+400	New	+$88.7K	﹤0.01%	1875

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lido Advisors's ABBV Position: Q1 2026 in Review

Lido Advisors increased its AbbVie (ABBV) stake by 2.7% in Q1 2026, buying an estimated $2.51M and bringing the position to 432,465 shares worth $94.1M. The position accounts for 0.29% of the portfolio, ranked #57.

Lido Advisors first reported a position in ABBV in Q1 2016 and has held it in 41 quarters since. The position peaked at $97.4M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Lido Advisors held 432,465 shares of AbbVie worth $94.1M as of Q1 2026.
Lido Advisors bought 11,334 AbbVie shares in Q1 2026, an estimated $2.51M.
AbbVie made up 0.29% of Lido Advisors's portfolio in Q1 2026, its #57 holding.
Lido Advisors first reported a position in AbbVie in Q1 2016 and has held it in 41 quarters since.
Lido Advisors's AbbVie position peaked at $97.4M in Q4 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.